BPC-157 + TB-500 + GHK-Cu · UK research stock

Each active is included for a different proposed route to tissue repair. BPC-157 has been investigated for angiogenesis, with work linking its effects to VEGFR2 activation and upregulation in endothelial cells ^[1][2]. TB-500 and thymosin beta-4 have been studied for actin sequestration, cell migration and wound closure across musculoskeletal and soft tissue models ^[3]. GHK-Cu has been examined as a copper carrier with reported influence on collagen and extracellular matrix turnover in skin. The rationale for combining them is that the three act on separate steps of repair; that rationale has not itself been tested in published work.

The evidence base is almost entirely preclinical. BPC-157 findings come largely from rodent injury models and cell work, with no substantial published human trial data ^[1]. Thymosin beta-4 literature includes cell and animal studies alongside a limited clinical record, and reviews describe the human picture as unsettled ^[3]. GHK-Cu has the longest topical and cosmetic research history of the three, though systemic data are thin. None of the three is an approved medicine, and BPC-157 and TB-500 fall under WADA prohibitions in sport. No peer-reviewed study of the blend as sold exists.